BOSTON, July 19, 2022 /PRNewswire/ -- HotSpot
Therapeutics, Inc., a biotechnology company pioneering the
discovery and development of small molecule allosteric therapies
for the treatment of cancer and autoimmune diseases, today
announced the appointment of Jose "Pepe" Carmona to its Board of
Directors. Mr. Carmona brings over 20 years of leadership
experience in the biopharmaceutical industry across a range of
roles and therapeutic areas.
"We are thrilled to welcome Pepe to our Board of Directors,"
said Jonathan Montagu, Co-Founder
and Chief Executive Officer of HotSpot Therapeutics. "Pepe's
significant expertise in financial leadership in the
biopharmaceutical sector will be invaluable as HotSpot continues to
grow and evolve, particularly as we move toward our goal of
becoming a clinical-stage company."
Mr. Carmona currently serves as Chief Financial Officer of
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is biologically engineering red
blood cells to create a new class of cellular medicines for the
treatment of cancer and autoimmune diseases, where he is
responsible for all the financial aspects of the business, as well
as business development, information technology and procurement.
Mr. Carmona previously served as the Chief Financial Officer of
Radius Health, a biopharmaceutical company developing and
commercializing endocrine therapeutics. Prior to joining Radius, he
was Chief Financial Officer of Innocoll Holdings PLC, acquired by
Gurnet Point L.P. Previously, he held numerous financial management
positions with increasing responsibilities at Novartis AG, in
various divisions, as Chief Financial Officer in Europe, North
America, Latin America and
held other senior global financial roles. Mr. Carmona currently
serves on the Board of Directors of Senda Biosciences. Mr. Carmona
received his B.S. in Industrial Civil Engineering from Universidad
Tecnica Federico Santa Maria in Valparaiso, Chile, and his M.B.A. from Columbia Business School in New York City.
"HotSpot is pioneering a novel and innovative approach to
allosteric drug discovery and development, and I am proud to join
the Board of Directors at this exciting point in the Company's life
cycle," said Mr. Carmona. "I look forward to working with this
passionate and innovative team as they advance small molecule
allosteric therapies for the treatment of cancer and autoimmune
disease."
About HotSpot Therapeutics, Inc.
HotSpot Therapeutics,
Inc. is targeting naturally occurring pockets on certain proteins
that it refers to as "natural hotspots" that are decisive in
controlling cellular protein function. Largely unexploited by
industry, these pockets have significant potential for drug
discovery and provide for the systematic design of highly potent
and selective small molecules that exhibit novel pharmacology. The
company's proprietary Smart Allostery™ platform utilizes
computational approaches and AI-driven data mining of large and
highly diverse data sets to identify natural hotspots, integrated
with a tailored pharmacology toolkit and bespoke chemistry which
the company believes will enable rapid delivery of superior
hotspot-targeted small molecules. HotSpot has established a
pipeline of differentiated allosteric small molecules for the
treatment of cancer and autoimmune diseases. To learn more,
visit www.hotspotthera.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hotspot-therapeutics-appoints-jose-carmona-to-board-of-directors-301588532.html
SOURCE HotSpot Therapeutics